Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03826693 · ClinicalTrials.gov registry record · Phase 2
Efficacy of Nitrous Oxide in OCD: Pilot Study
A Phase 2 study of Obsessive - Compulsive Disorder, sponsored by Stanford University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
- 1
- Study location
NCT03826693: Recruiting Phase 2 study of Obsessive - Compulsive Disorder, sponsored by Stanford University.
NCT03826693 is a Phase 2 study of Obsessive - Compulsive Disorder that is actively recruiting participants, run by Stanford University. The registered enrollment target is 45 participants, below the 2,064-participant average among 84 other Obsessive - Compulsive Disorder trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03826693, a Phase 2 study of Obsessive - Compulsive Disorder, is actively recruiting participants, sponsored by Stanford University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
- 1
- Study location
Study Summary
This study investigates whether the commonly used and well-tolerated inhaled anesthetic nitrous oxide can rapidly improve symptoms of OCD.
Primary Outcome
Improvement in OCD severity is measured by the YBOCS (Yale Brown Obsessive-Compulsive Scale), a gold standard measure of obsessions and compulsions. For the YBOCS the minimum units are 0 and Maximum units on the total scale are 40. The higher the number on the YBOCS, the more severe the symptoms. Response is defined as at least a 35% reduction on the YBOCS.
Conditions Studied
Interventions
- DRUG Nitrous Oxide
- DRUG Nitrogen
Study Locations (1)
California
- Stanford University - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2021-04-17 |
| Est. Completion | 2027-10 |
| Phase | Phase 2 |
What NCT03826693 shows while recruiting
NCT03826693 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 2,064-participant average among 84 other Obsessive - Compulsive Disorder trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Obsessive - Compulsive Disorder appearing as the primary indexed condition, and to 2 interventions - of which Nitrous Oxide is the first listed.
NCT03826693 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT03826693 about?
NCT03826693 is a clinical study titled "Efficacy of Nitrous Oxide in OCD: Pilot Study". This study investigates whether the commonly used and well-tolerated inhaled anesthetic nitrous oxide can rapidly improve symptoms of OCD.
What is the current status of trial NCT03826693?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2021-04-17. Estimated completion is 2027-10.
What conditions does trial NCT03826693 study?
This clinical trial studies the following conditions: Obsessive - Compulsive Disorder.
What interventions are being tested in trial NCT03826693?
The interventions under investigation include: Nitrous Oxide (DRUG), Nitrogen (DRUG).
Who is sponsoring clinical trial NCT03826693?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03826693 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obsessive - Compulsive Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03826693's enrollment target sits among peer trials
45 47th of 84 higher than 36 of 84 other Obsessive - Compulsive Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obsessive - Compulsive Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
MDMA-Assisted CBT for OCD (MDMA-CBT4OCD Study)
RECRUITING · Phase 2
-
Search for Novel Transcranial Magnetic Stimulation (TMS) Targets for Mental Illness
RECRUITING · Phase 2
-
Examining Mu Opioid Mechanisms of Ketamine's Rapid Effects in OCD (MKET2)
RECRUITING · Phase 2
-
Study of Dextromethorphan in OCD and Related Disorders
RECRUITING · Phase 2
-
A Clinical Trial of Tolcapone in Obsessive Compulsive Disorder
ACTIVE NOT RECRUITING · Phase 2
-
Understanding How Ketamine Brings About Rapid Improvement in OCD
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI